AUA 2025 Annual Meeting
AUA 2025 Annual Meeting

The American Urological Association 2025 Annual Meeting is being held in Las Vegas, Nevada from April 26 to April 29.

Follow along with our exclusive updates from the meeting, featuring coverage of the most impactful sessions, groundbreaking research highlights, and exclusive video interviews with leading urologists.

Advertisement

Latest News

Consolidative Surgery After EVP Immunotherapy Shows Promising Pathologic Response in Advanced Urothelial Carcinoma
Consolidative Surgery After EVP Immunotherapy Shows Promising Pathologic Response in Advanced Urothelial Carcinoma
Brandon TwyfordAdvanced Urothelial Carcinoma | April 26, 2025
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
Comparing the Sensitivity and Specificity of PET Imaging for Staging of MIBC
Comparing the Sensitivity and Specificity of PET Imaging for Staging of MIBC
Emily MenendezMuscle Invasive Urothelial Carcinoma | April 26, 2025
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Study Suggests Focal Therapy May Be Feasible for Select Patients With High-Risk Prostate Cancer
Study Suggests Focal Therapy May Be Feasible for Select Patients With High-Risk Prostate Cancer
Brandon TwyfordProstate Cancer | April 26, 2025
Focal therapy may be feasible in select men with GG4 prostate cancer, showing similar success rates to GG2/GG3 disease.
PROs From Patients With Localized Prostate Cancer Receiving HIFU: 3-Year Update
PROs From Patients With Localized Prostate Cancer Receiving HIFU: 3-Year Update
Zachary BessetteLocalized | April 26, 2025
Research sheds light on the patient-reported outcomes from a 3-year focal therapy program for localized PCa using HIFU.
5-Year Outcomes of Focal Cryoablation and Focal High-Intensity Focused Ultrasound for Localized Prostate Cancer
5-Year Outcomes of Focal Cryoablation and Focal High-Intensity Focused Ultrasound for Localized Prostate Cancer
Emily MenendezLocalized | April 26, 2025
Hemi-gland cryoablation and HIFU provided acceptable and eminent functional outcomes in patients over a 5-year follow-up.
Histologic Subtype Not Linked to Cancer-Specific Survival After Robotic Partial Nephrectomy, Study Finds
Histologic Subtype Not Linked to Cancer-Specific Survival After Robotic Partial Nephrectomy, Study Finds
Brandon TwyfordRenal Cell Carcinoma | April 26, 2025
Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.
Patients With ccRCC and nccRCC With Tumor Thrombus Experience Similar Outcomes After Surgery
Patients With ccRCC and nccRCC With Tumor Thrombus Experience Similar Outcomes After Surgery
Emily MenendeznccRCC | April 26, 2025
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
SUNNIFORECAST Results: Nivo/Ipi Provides Beneficial OS Boost at 12 Months Over SOC
SUNNIFORECAST Results: Nivo/Ipi Provides Beneficial OS Boost at 12 Months Over SOC
Emily MenendeznccRCC | April 16, 2025
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Beyond EV/Pembro and NIAGARA: Is There a Role for IO Rechallenge?
Beyond EV/Pembro and NIAGARA: Is There a Role for IO Rechallenge?
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Pembro Rechallenge in Urothelial Cancer: A Post Hoc Analysis of KEYNOTE Trials
Pembro Rechallenge in Urothelial Cancer: A Post Hoc Analysis of KEYNOTE Trials
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | April 15, 2025
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
ADT Plus Radiotherapy Provides Benefits Past 30 Months for Localized PCa
ADT Plus Radiotherapy Provides Benefits Past 30 Months for Localized PCa
Emily MenendezLocalized | April 14, 2025
The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhD
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Christopher Wallis, MD, PhD, FRCSC
Christopher Wallis, MD, PhD, FRCSCAssistant Professor of Urology | University of Toronto
Akhil Abraham Saji, MD
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MD
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Beyond the Operating Room: Compassionate Care, Leadership, and Mentorship in Urology With Dr. Christopher Kane
Christopher Kane, MDProstate Cancer | March 24, 2025
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and lead in urology.

Conference Coverage

Live meeting highlights

Consolidative Surgery After EVP Immunotherapy Shows Promising Pathologic Response in Advanced Urothelial Carcinoma
Brandon TwyfordAdvanced Urothelial Carcinoma | April 26, 2025
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
Read More
Comparing the Sensitivity and Specificity of PET Imaging for Staging of MIBC
Emily MenendezMuscle Invasive Urothelial Carcinoma | April 26, 2025
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Read More
Study Suggests Focal Therapy May Be Feasible for Select Patients With High-Risk Prostate Cancer
Brandon TwyfordProstate Cancer | April 26, 2025
Focal therapy may be feasible in select men with GG4 prostate cancer, showing similar success rates to GG2/GG3 disease.
Read More
PROs From Patients With Localized Prostate Cancer Receiving HIFU: 3-Year Update
Zachary BessetteLocalized | April 26, 2025
Research sheds light on the patient-reported outcomes from a 3-year focal therapy program for localized PCa using HIFU.
Read More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |